Agenus announces positive interim data from balstilimab and zalifrelimab clinical trials in second-line cervical cancer

Agenus announces positive interim data from balstilimab and zalifrelimab clinical trials in second-line cervical cancer.agenus inc - balstilimab and zalifrelimab combination yield more than 20% response rates.agenus inc - on track to submit 2 blas for these agents in 2020.agenus inc - low-dose agen1181 monotherapy demonstrated a confirmed complete response in a patient with difficult-to-treat endometrial cancer.agenus inc - balstilimab and zalifrelimab combination yield >20% response rates.
AGEN Ratings Summary
AGEN Quant Ranking